In colorectal cancer, for instance, B-RAF inhibitors alone are ineffective due to EGFR reactivation, but the combination of B-RAF + MEK + EGFR inhibitors has demonstrated significant survival benefits, underscoring the necessity of combination regimens in certain tumor types [39]. This evidence concerns the gene BRAF and neoplasm.